Latvia - Latvian - Zāļu valsts aģentūra

ferring hellas, greece - testosterons - gels - 50 mg

European Union - Latvian - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostatas audzēji - endokrīnā terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

European Union - Latvian - EMA (European Medicines Agency)

accord healthcare s.l.u. - relugolix - prostatas audzēji - endokrīnā terapija - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

European Union - Latvian - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - prostatas audzēji - endokrīnā terapija - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

European Union - Latvian - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatas audzēji - citi hormonu antagonisti un tiem līdzīgas vielas - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

European Union - Latvian - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterona acetāts - prostatas audzēji - endokrīnā terapija - zytiga ir apzīmēti ar prednizonu vai prednizolons:ārstētu metastātisku kastrācija izturīgs prostatas vēzis pieauguši vīrieši, kas ir asimptomātiski vai daļēji simptomātiska pēc neveiksmes androgēnu atņemšanu terapija, kuriem ķīmijterapijas vēl nav klīniski indicatedthe attieksmi metastātisku kastrācija izturīgs pret prostatas vēzi, pieaugušo, vīriešu, kuru slimība ir progresējusi vai pēc docetaxel, pamatojoties ķīmijterapijas režīmu.

European Union - Latvian - EMA (European Medicines Agency)

accord healthcare s.l.u. - abiraterona acetāts - prostatas audzēji - endokrīnā terapija - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

European Union - Latvian - EMA (European Medicines Agency)

krka, d.d., novo mesto - abiraterona acetāts - prostatas audzēji - endokrīnā terapija - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

European Union - Latvian - EMA (European Medicines Agency)

virbac s.a. - osaterone acetāts - uroloģiskie līdzekļi - suņi - labdabīgas prostatas hipertrofijas (bph) ārstēšana suņiem vīriešiem.

European Union - Latvian - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - imunoloģiskie līdzekļi suidae - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. vēl viens būtisks lopbarības piesārņojuma veicinātājs, skatols, var tikt samazināts kā netiešs efekts. agresīva un seksuāla (stiprinoša) uzvedība arī tiek samazināta. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).